Skip to content Skip to sidebar Skip to footer

Recce Pharmaceuticals (ASX: RCE) Secures A$85M R&D Backing: Is It a Buy Before Phase 3 Results?

Recce secures A$85m R&D backing as Phase 3 nears Recce Pharmaceuticals (ASX: RCE) hit a one-week high after landing an A$85 million Advanced Overseas Finding from AusIndustry. This ruling is…

ByUjjwal Maheshwari

Nov 2024

Healthcare Stocks Life Sciences Mid Cap Stocks Small Caps Stocks

Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results

There are encouraging signs from Recce Pharmaceuticals' (ASX:RCE) Phase 2 ABSSSI Clinical Trial (Acute Bacterial Skin and Skin Structure Infections). The trial, is nearing completion, but the results to date…

ByNick Sundich

Oct 2024

Healthcare Stocks Life Sciences

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Investors should expect to see more ASX biotechs focus on Asia in the years ahead. And there are good reasons why. For many companies, the golden market has been the USA,…

ByNick Sundich

Sep 2024

Education Healthcare Stocks

Here’s what you need to know about the TGA Special Access Scheme and why its a game changer for ASX biotechs

For ASX biotechs wishing to commercialise drugs in Australia, the Therapeutic Goods Administration (TGA) Special Access Scheme is the next best thing to regulatory approval. Therapeutic goods need to be included…

ByNick Sundich

Jun 2024

Healthcare Stocks

How to minimise the risks of biotech shares on the ASX? Here are 4 traits investors should look for

To minimise the risks of biotech shares is a major challenge for investors, but not one that is insurmountable. The biotech sector on the ASX represents a substantial opportunity for…

ByNick Sundich

May 2024

Healthcare Stocks Small Caps Stocks

Recce Pharmaceuticals (ASX:RCE): Taking the fight against superbugs to the next level

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) is a Sydney-based company fighting the battle against superbugs, with a legitimate chance of succeeding if the data to date is any guide. Bacterial infections have…

ByNick Sundich

Apr 2024

Uncategorized

5 ASX Health stocks to add to your porfolio

5 ASX Health Stocks Stuart Roberts from Stocks Down Under discussed the potential promise of biotech, sharing his perspectives about the industry's future amidst changing interest rates. He compares the…

ByMarc Kennis

the Kick-ass Multipurpose WordPress Theme

Recce Pharmaceuticals (ASX: RCE) Secures A$85M R&D Backing: Is It a Buy Before Phase 3 Results?

Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Here’s what you need to know about the TGA Special Access Scheme and why its a game changer for ASX biotechs

How to minimise the risks of biotech shares on the ASX? Here are 4 traits investors should look for

Recce Pharmaceuticals (ASX:RCE): Taking the fight against superbugs to the next level

5 ASX Health stocks to add to your porfolio

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here